Literature DB >> 21533607

Chromogranin peptides in brain diseases.

Michael Willis1, Irmgard Leitner, Kurt A Jellinger, Josef Marksteiner.   

Abstract

Synaptic disturbances may play a key role in the pathophysiology of neuropsychiatric diseases. In this article, we review immunohistological findings of chromogranin peptides in neurodegenerative and neurodevelopmental disorders, with particular emphasis on Alzheimer's disease, the disorder chromogranins have been studied most extensively. Data was collected from existing and new experimental data and medline research. This review focuses on synaptic changes elicited by chromogranin peptides immunoreactivity in Alzheimer's disease, as well in schizophrenia and amyotrophic lateral sclerosis (ALS). An imbalanced availability of chromogranin peptides may be responsible for impaired neurotransmission and a reduced functioning of dense core vesicles. Since chromogranin A was postulated as a potent proinflammatory agent, we focused on chromogranin A in neuroinflammation in Alzheimer's disease and ALS. Further understanding of role and function of chromogranin peptides in neuropathological conditions is still required.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21533607     DOI: 10.1007/s00702-011-0648-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  68 in total

1.  PE-11, a peptide derived from chromogranin B, in the human brain.

Authors:  J Marksteiner; R Bauer; W A Kaufmann; E Weiss; U Barnas; H Maier
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

Review 2.  A review on electron microscopy and neurotransmitter systems.

Authors:  Fernando Torrealba; Maria Angélica Carrasco
Journal:  Brain Res Brain Res Rev       Date:  2004-12

3.  Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles.

Authors:  H Lassmann; R Weiler; P Fischer; C Bancher; K Jellinger; E Floor; W Danielczyk; F Seitelberger; H Winkler
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

4.  Expression of scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid.

Authors:  Rodrigo Alarcón; Carolina Fuenzalida; Marcos Santibáñez; Rommy von Bernhardi
Journal:  J Biol Chem       Date:  2005-06-29       Impact factor: 5.157

5.  Secretoneurin releases dopamine from rat striatal slices: a biological effect of a peptide derived from secretogranin II (chromogranin C).

Authors:  A Saria; J Troger; R Kirchmair; R Fischer-Colbrie; R Hogue-Angeletti; H Winkler
Journal:  Neuroscience       Date:  1993-05       Impact factor: 3.590

6.  Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia.

Authors:  M Landén; B Grenfeldt; P Davidsson; M Stridsberg; B Regland; C G Gottfries; K Blennow
Journal:  Eur Neuropsychopharmacol       Date:  1999-06       Impact factor: 4.600

7.  Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins.

Authors:  S L Eastwood; P J Harrison
Journal:  Brain Res Bull       Date:  2001-07-15       Impact factor: 4.077

8.  Proteomic analysis of proteins in PC12 cells before and after treatment with nerve growth factor: increased levels of a 43-kDa chromogranin B-derived fragment during neuronal differentiation.

Authors:  C M Huang; H A Shui; Y T Wu; P W Chu; K G Lin; L S Kao; S T Chen
Journal:  Brain Res Mol Brain Res       Date:  2001-08-15

9.  Differential effects of phencyclidine application on secretogranin II expression in organotypic slices of rat prefrontal cortex.

Authors:  Josef K Hinterhoelzl; Kayvon Salimi; Christian Humpel; Nicolas Singewald; Christine Adlassnig; Reiner Fischer-Colbrie; Wolfgang W Fleischhacker; Josef Marksteiner
Journal:  J Neurochem       Date:  2003-10       Impact factor: 5.372

Review 10.  The chromogranins A and B: the first 25 years and future perspectives.

Authors:  H Winkler; R Fischer-Colbrie
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

View more
  15 in total

1.  Hindered submicron mobility and long-term storage of presynaptic dense-core granules revealed by single-particle tracking.

Authors:  B A Scalettar; C Jacobs; A Fulwiler; L Prahl; A Simon; L Hilken; J E Lochner
Journal:  Dev Neurobiol       Date:  2012-06-21       Impact factor: 3.964

2.  Cerebrospinal fluid levels of chromogranin A in the treatment-naïve early stage Parkinson's disease: a pilot study.

Authors:  Michaela Kaiserová; Hana Přikrylová Vranová; David Stejskal; Kateřina Menšíková; Petr Kaňovský
Journal:  J Neural Transm (Vienna)       Date:  2013-04-16       Impact factor: 3.575

3.  Integrated multi-cohort transcriptional meta-analysis of neurodegenerative diseases.

Authors:  Matthew D Li; Terry C Burns; Alexander A Morgan; Purvesh Khatri
Journal:  Acta Neuropathol Commun       Date:  2014-09-04       Impact factor: 7.801

4.  Catestatin exerts direct protective effects on rat cardiomyocytes undergoing ischemia/reperfusion by stimulating PI3K-Akt-GSK3β pathway and preserving mitochondrial membrane potential.

Authors:  Eleonora Bassino; Sara Fornero; Maria Pia Gallo; Clara Gallina; Saveria Femminò; Renzo Levi; Bruno Tota; Giuseppe Alloatti
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

5.  Amyloid-β Impairs Vesicular Secretion in Neuronal and Astrocyte Peptidergic Transmission.

Authors:  Virginia Plá; Neus Barranco; Esther Pozas; Fernando Aguado
Journal:  Front Mol Neurosci       Date:  2017-06-28       Impact factor: 5.639

6.  CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders.

Authors:  N Mattsson; P Insel; R Nosheny; H Zetterberg; J Q Trojanowski; L M Shaw; D Tosun; M Weiner
Journal:  Transl Psychiatry       Date:  2013-08-20       Impact factor: 6.222

7.  Neuroanatomical Correlates of Recognizing Face Expressions in Mild Stages of Alzheimer's Disease.

Authors:  Laurie-Anne Sapey-Triomphe; Rolf A Heckemann; Nawele Boublay; Jean-Michel Dorey; Marie-Anne Hénaff; Isabelle Rouch; Catherine Padovan; Alexander Hammers; Pierre Krolak-Salmon
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

8.  Identification of prefrontal cortex protein alterations in Alzheimer's disease.

Authors:  Maria Garranzo-Asensio; Pablo San Segundo-Acosta; Javier Martínez-Useros; Ana Montero-Calle; María Jesús Fernández-Aceñero; Anna Häggmark-Månberg; Alberto Pelaez-Garcia; Mayte Villalba; Alberto Rabano; Peter Nilsson; Rodrigo Barderas
Journal:  Oncotarget       Date:  2018-01-24

Review 9.  A comprehensive systematic review of CSF proteins and peptides that define Alzheimer's disease.

Authors:  Juan R Peinado; Yoana Rabanal-Ruiz; Cristina M Pedrero-Prieto; Sonia García-Carpintero; Javier Frontiñán-Rubio; Emilio Llanos-González; Cristina Aguilera García; Francisco J Alcaín; Iris Lindberg; Mario Durán-Prado
Journal:  Clin Proteomics       Date:  2020-06-05       Impact factor: 3.988

10.  Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.

Authors:  Flora H Duits; Gunnar Brinkmalm; Charlotte E Teunissen; Ann Brinkmalm; Philip Scheltens; Wiesje M Van der Flier; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Res Ther       Date:  2018-01-15       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.